EUCTR2007-001337-34-GB进行中（未招募）不适用
A double-blind, randomised, cross-over, multi-centre study, to evaluate onset of effect in the morning in patients with severe Chronic Obstructive Pulmonary Disease (COPD) treated with budesonide/formoterol (Symbicort®Turbuhaler®) 320/9 µg, compared with salmeterol/fluticasone (Seretide® Diskus®) 50/500 µg, both given as one inhalation twice daily for one week each. - SPEED
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For inclusion in the study patients must fulfil all of the following criteria:
- •1. Provision of informed consent prior to conducting any study-related procedures.
- •2. Outpatient, female or male aged =40 years.
- •3. A clinical diagnosis of COPD with symptoms for more than 2 years, prior to visit 2.
- •4. A current or previous smoker with a smoking history =10 pack years (1 pack year
- •= 20 cigarettes smoked per day for one year).
- •5. FEV1 =50% of predicted normal value, pre-bronchodilator.
- •6. FEV1/VC <70%, pre-bronchodilator.
- •7. Previous use of a short-acting inhaled bronchodilator (ß2-agonist or anticholinergics) as reliever medication.
- •8. A history of at least one COPD exacerbation requiring a course of oral steroids and/or antibiotics within 1 to 12 months prior to visit 2.
- •9. Able to read and write and use the electronic devices (eDiary and ePEF).
- •To be randomised the patient must fulfil the following criteria at Visit 3:
- •10. Total morning symptoms score of at least 2 (GCSQ score) on 5 out of the last 7 days of the run-in period, excluding day of visit 3.
- •11. Complete morning records of PEF data on at least 5 out of the last 7 days of the run-in period, excluding day of visit 3.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any of the following is regarded as a criterion for exclusion from the study:
- •1. A history of asthma.
- •2. A history of seasonal allergic rhinitis before 40 years of age.
- •3. Significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart
- •failure, uncontrolled hypertension as defined by the investigator, or any other relevant cardiovascular disorder, as judged by the investigator.
- •4. Any current respiratory tract disorder other than COPD, which is considered by the investigator to be clinically significant.
- •5. Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patients ability to participate in the study.
- •6. Patients taking oral or ophthalmic non-cardioselective ß-blocking agents.
- •7. Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator.
- •8. Regular oxygen therapy.
- •9. Known or suspected hypersensitivity to study therapy or excipients of the investigational products.
- •10. Scheduled in-patient hospitalization during the course of the study.
- •11. Patients who have participated in a clinical study evaluating an investigational
- •drug in the last 4 weeks (3 months in the UK) prior to visit 2, or who have been previously allocated a randomisation code in this study.
- •12. Patients with a history of chronic alcohol or drug abuse or any condition associated with poor compliance.
- •13. Patient participating in or scheduled for an intensive COPD rehabilitation
- •programme during the course of the study.
- •14. Any clinically relevant abnormal findings in clinical, physical examination, and vital signs at Visit 2, which in the opinion of the investigator(s) may put the patient at risk because of his/her participation in the study (to be checked before allocation of randomisation code at Visit 3).
- •15. Exacerbation of COPD during run-in or within 4 weeks prior to visit 2 (from end
- •of exacerbation), requiring hospitalisation, a course of oral and/or increased doses of inhaled steroids and/or antibiotics
- •and/or inhaled steroids and/or antibiotics.
- •16. Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
- •17. Use of Oral/parenteral glucocorticosteroids within 4 weeks prior to Visit 2
研究者
相似试验
进行中（未招募）
1 期
A double-blind, randomised, cross-over, multi-centre study, to evaluate onset of effect in the morning in patients with severe Chronic Obstructive Pulmonary Disease (COPD) treated with budesonide/formoterol (Symbicort®Turbuhaler®) 320/9 µg, compared with salmeterol/fluticasone (Seretide® Diskus®) 50/500 µg, both given as one inhalation twice daily for one week each. - SPEEDSevere Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2007-001337-34-DKAstraZeneca AB420
进行中（未招募）
不适用
A double-blind, randomised, cross-over, multi-centre study, to evaluate onset of effect in the morning in patients with severe Chronic Obstructive Pulmonary Disease (COPD) treated with budesonide/formoterol (Symbicort®Turbuhaler®) 320/9 µg, compared with salmeterol/fluticasone (Seretide® Diskus®) 50/500 µg, both given as one inhalation twice daily for one week each. - SPEEDEUCTR2007-001337-34-DEAstraZeneca AB420
进行中（未招募）
1 期
A double-blind, randomised, cross-over, multi-centre study, to evaluate onset of effect in the morning in patients with severe Chronic Obstructive Pulmonary Disease (COPD) treated with budesonide/formoterol (Symbicort®Turbuhaler®) 320/9 µg, compared with salmeterol/fluticasone (Seretide® Diskus®) 50/500 µg, both given as one inhalation twice daily for one week each. - SPEEDSevere Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2007-001337-34-BEAstraZeneca AB420
进行中（未招募）
1 期
A double-blind, randomized, cross-over, multi-center efficacy and safety study of ibuprofen plus hyoscine butylbromide for pain management due to primary dysmenorrheaEUCTR2022-000843-57-BGRONTIS HELLAS S.A.54
进行中（未招募）
不适用
A double-blind, randomised, controlled, multi-centre safety study of a refrigerator-stable formulation of VARIVAX® in healthy 12 to 15 month-old infants.EUCTR2004-002669-19-ITAVENTIS PASTEUR MSD S.P.A.